{{Rsnum
|rsid=3774426
|Gene=CACNA1D
|Chromosome=3
|position=53524975
|Orientation=plus
|GMAF=0.2557
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CACNA1D
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 35.4 | 46.2 | 18.5
| HCB | 64.4 | 28.9 | 6.7
| JPT | 74.4 | 23.3 | 2.3
| YRI | 77.8 | 19.0 | 3.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 64.4 | 28.9 | 6.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs3774426]] is a SNP in the calcium channel, voltage-dependent, L type, alpha 1D subunit [[CACNA1D]] gene.

A study of 161 Japanese patients (85 men, 76 women) being treated for [[hypertension]] with L-type dCCBs ([[calcium channel blocker]]s) concluded that individuals with [[rs3774426]](C;C) genotypes responded better, as measured by lowered systolic and diastolic blood pressure readings.{{PMID|19225208}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}